(MedPage Today) — Fewer American women are having babies — except unmarried women and those in their 40s — while the number of cesarean deliveries continues to climb, according to CDC vital statistics for 2008.
No Comments »
Filed under: General Health News
A national clinical trial, which opens imminently, will aim to assess the impact of a novel anti-cancer drug in the setting of donor bone marrow transplantation for myeloma.
No Comments »
Filed under: Pharmacy News
Emisphere Technologies, Inc. and Novo Nordisk A/S today announced that they have entered into an exclusive Development and License Agreement to develop and commercialize oral formulations of Novo Nordisk’s insulins, which have the potential of treating diabetes, using Emisphere’s Eligen® Technology. This is the second license agreement between the two companies. The first agreement, for [...]
No Comments »
Filed under: Pharmacy News
Genzyme Corporation today provided an extensive briefing on the market potential of alemtuzumab for multiple sclerosis at an event for investors and analysts in New York.
No Comments »
Filed under: Pharmacy News
The language that doctors use with low-income, rural patients can help determine whether these patients agree to participate in clinical trials testing new cancer treatments, a new study found.
No Comments »
Filed under: Pharmacy News
Amylin Pharmaceuticals, Inc. today announced that it has submitted the initial sections of a rolling submission for a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for the use of metreleptin to treat diabetes and/or hypertriglyceridemia (high levels of triglycerides in the bloodstream) in patients with rare forms of lipodystrophy.
No Comments »
Filed under: Pharmacy News
Incyte Corporation announced today positive top-line results from COMFORT-I, the pivotal Phase III clinical trial of INCB18424 (also known as INC424) in patients with myelofibrosis (MF) being conducted under a Food and Drug Administration (FDA) Special Protocol Assessment (SPA) Agreement. COMFORT-I (COntrolled MyeloFibrosis Study with ORal JAK Inhibitor Treatment) is a double-blind, placebo-controlled Phase III [...]
No Comments »
Filed under: Pharmacy News
Ambit Biosciences, today announced that it has initiated separate Phase I trials for two products AC430, a selective Janus Kinase 2 (JAK2) inhibitor, and AC480, a pan-HER inhibitor.
No Comments »
Filed under: Pharmacy News
VistaGen Therapeutics, Inc., a stem cell technology company focused on drug discovery and development, today announced the successful completion of its initial Phase 1 safety study of AV-101, the Company’s novel orally available prodrug candidate for treatment of neuropathic pain. Neuropathic pain, a serious and chronic condition causing pain after an injury or disease of [...]
No Comments »
Filed under: Pharmacy News
Bristol-Myers Squibb Company and Oncolys BioPharma Inc., a privately held biotechnology company based in Japan, announced today that the companies have signed a definitive agreement under which Bristol-Myers Squibb will acquire exclusive worldwide rights to manufacture, develop and commercialize festinavir, a once-a-day, orally available nucleoside reverse transcriptase inhibitor (NRTI) in Phase II development for HIV.
No Comments »
Filed under: Pharmacy News
